Results from a meta-analysis support use of immune checkpoint inhibitors for the treatment of sarcomatoid renal cell carcinoma.

Results from a meta-analysis support use of immune checkpoint inhibitors for the treatment of sarcomatoid renal cell carcinoma.

Immune checkpoint inhibitors achieve high response rates and prolonged overall survival among patients with pulmonary sarcomatoid carcinoma when used in the second- or later-line, report researchers.

Ziad Bakouny outlines his research into the determinants of the poor prognosis and response to immune checkpoint inhibitors seen in patients with sarcomatoid and rhabdoid renal cell carcinoma (4:14). This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

A meaningful proportion of patients with advanced renal cell carcinoma with variant histology or sarcomatoid differentiation respond to the immunotherapy combination of atezolizumab and bevacizumab without experiencing severe toxicity, phase II study data show.

Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.

The combination of pembrolizumab and lenvatinib has durable antitumor activity and promising survival outcomes in treatment-naïve patients with advanced non-clear-cell renal cell carcinoma, say the KEYNOTE-B61 investigators.

Adding regional hyperthermia to neoadjuvant chemotherapy significantly improves survival in patients with localized high-risk soft tissue sarcoma, researchers report.

Presented by Bernd Kasper University Medical Centre Mannheim, Mannheim, Germany. Gain and test your knowledge in this interactive case study, looking at best practice management of patients with Soft tissue sarcoma (STS), and gain knowledge on emerging combination therapy options for advanced STS. This case study is intended for medical oncologists, surgical oncologists, radiation oncologists and any other clinicians with a strong interest and/or expertise in the treatment of patients with soft-tissue sarcoma (STS). This programme was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare IME

Immunotherapy could have a role in the treatment of patients with certain sarcoma subtypes in the advanced disease setting, suggests research presented at the 2017 annual meeting of the American Society of Clinical Oncology. Here we provide a round-up of three studies investigating various immunotherapeutic strategies in advanced sarcoma patients.

The doxorubicin conjugate aldoxorubicin could be a suitable alternative to standard therapies for patients with relapsed or refractory soft tissue sarcoma, say researchers.

With regard to efficacy, the highest ORRs were observed among participants with nonmelanoma skin cancer, Hodgkin’s lymphoma, or Kaposi’s sarcoma, at 69%, 67%, and 60%, respectively, followed by rates of 47% among those with melanoma and 31% among those with NSCLC.